You are here

Article Text

Article menu
Download PDFPDF
State of the art review
Endotyping, phenotyping and personalised therapy in obstructive sleep apnoea: are we there yet?
  1. Chris D Turnbull1,2,3,4,
  2. John R Stradling4
  1. 1 Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  2. 2 Nuffield Department of Medicine, University of Oxford, Oxford, UK
  3. 3 Oxford Centre for Respiratory Medicine, NIHR Oxford Biomedical Research Centre, Oxford, UK
  4. 4 NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
  1. Correspondence to Dr Chris D Turnbull, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; christopher.turnbull{at}ouh.nhs.uk

Abstract

Obstructive sleep apnoea (OSA) was traditionally thought to be mainly caused by obesity and upper airway crowding, and hence OSA management was not personalised according to particular characteristics, with most symptomatic patients receiving continuous positive airway pressure therapy. Recent advances in our understanding have identified additional potential and distinct causes of OSA (endotypes), and subgroups of patients (phenotypes) with increased risk of cardiovascular complications. In this review, we discuss the evidence to date as to whether there are distinct clinically useful endotypes and phenotypes of OSA, and the challenges to the field in moving towards delivering personalised therapy in OSA.

  • Sleep apnoea

https://doi.org/10.1136/thorax-2023-220037

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @drchristurnbull

    • Contributors CDT and JS conceived the review. CDT wrote the first draft of the manuscript and both authors edited and contributed to the final draft of the manuscript. All authors read and approved the final version of the manuscript. CDT is responsible for the overall content as the guarantor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Disclaimer The views expressed are those of the authors and not necessarily of the NHS, the NIHR, or the Department of Health.

    • Competing interests CDT reports honoraria from Stowood Scientific, outside the scope of this submission. There are no other relevant competing interests.

    • Provenance and peer review Commissioned; externally peer reviewed.